February 2024 FDA Recall Drug by Stason Pharmaceuticals, Inc.
D-0367-2024 - Failed Dissolution Specifications

This Class III drug recall was voluntarily initiated by Stason Pharmaceuticals, Inc. on February 9, 2024 for the product Drug. The FDA reported the reason for recall as failed dissolution specifications. The product was distributed Nationwide and the recall is currently terminated.

Recall Number: D-0367-2024

Reason for Recall
Failed Dissolution Specifications: results slightly under spec at at 9-months.
Initiated
02-09-2024
Reported
03-13-2024
Quantity
54, 131 bottles

Recall Profile & Regulatory Data

Class III - is a situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences.
Stason Pharmaceuticals, Inc.
Mercaptopurine Tablets, USP 50 mg, packaged in: a) 25-count bottle (NDC 69076-913-02), b) 250-count bottle (NDC 69076-913-25), Rx only, Manufactured for: Quinn Pharmaceuticals, Boca Raton, FL, www.quinnrx.com

Batch or Lot Expiration Information

Lot# : a)22K012, 22K013A, Exp: 04/30/2024; 23A001, 23A002A, Exp: 07/31/2024; 23D006, 23D007A, 23D007C, Exp:10/31/2024; b)22K013B, Exp: 04/30/2024; 23A002B, Exp:07/31/2024; 23D007B, Exp: 10/31/2024.